A Clinical Study of Pelvic Concurrent Chemoradiotherapy Combined with CT-guided Intracavitary Brachytherapy with Adaptive Simultaneous Dose Escalation for Locally Advanced Cervical Cancer

NCT ID: NCT06882473

Last Updated: 2025-03-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-15
• Study Completion Date: 2027-03-15

Brief Summary

The standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiotherapy with external beam radiotherapy (EBRT) and Brachytherapy (BT). overall treatment time (OTT) has been found to be an important predictor of treatment response. Some studies have shown that the acceleration of tumor cell regeneration during the extension of radiotherapy leads to poor local control. Prolonging the overall treatment time of cervical cancer radiotherapy for more than 8 weeks leads to an increase in pelvic local control failure. Therefore, shortening OTT has great potential benefits from both clinical efficacy and social benefits. Shortening OTT in radical cervical cancer radiotherapy includes hypofractionated EBRT and shortening the interval between BT and EBRT. However, further shortening OTT may lead to an increase in acute and late toxicity. Adaptive radiotherapy (ART) strategies systematically monitor variations in target and neighbouring structures to inform treatment-plan modification during radiotherapy. The application of image-guided adaptive brachytherapy (IGABT) has clearly demonstrated the advantages of this approach in the treatment of cervical cancer. Previous studies have shown that the implementation of IGABT can achieve personalized treatment, dose increase, improve clinical efficacy, reduce normal tissue toxicity and side effects, and strengthen international standardized quality control. In this study, online adaptive pelvic EBRT combined with IGABT based on uRT-linac was performed under online CT guidance.

The aim of this study is to evaluate the safety and efficacy of pelvic concurrent chemoradiotherapy combined with CT-guided intracavitary brachytherapy with adaptive simultaneous dose escalation in locally advanced cervical cancer.

Conditions

Locally Advanced Cervical Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

treatment group

External beam radiation therapy: The patients are irradiated with 6MV X-rays at 1.8Gy per fraction, 5 fractions per week, with a total dose of 45-50.4Gy in 25-28 fractions for 5-6 weeks.

Brachytherapy: CT-guided 192Ir high dose rate brachytherapy is used, twice a week, on the same day as external beam radiation therapy, 6Gy per fraction, a total dose of 30Gy. The total radiotherapy dose shouldn't be less than 85Gy EQD2. The overall treatment time ≤ 45 days.

Chemotherapy: Cisplatin 40 mg/m2, d1, i.v. weekly. Six cycles of concurrent chemotherapy should be completed. Treatment continued until disease progression, unacceptable toxic effects happened, or a decision by the investigator and/or patient to discontinue treatment.

Group Type: EXPERIMENTAL

Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day

Intervention Type: OTHER

Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day.

Interventions

Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day

Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Sign the informed consent;

2. Age :18 to 75 years old;

3. Histologically or cytologically confirmed cervical cancer;

4. According to the International Federation of Gynecology and Obstetrics (FIGO 2018) stage IB3, IIA2, IIB, III, IV (local advanced), and had not received treatment before enrollment;

5. Measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;

6. ECOG physical performance score 0-2;

7. Expected survival time >= 3 months;

8. LVEF >= 55%;

9. Bone marrow function: neutrophil >= 1.5×109/L, platelet ≥ 100×109/L, white blood cell 4.0-10.0×109/L, hemoglobin >= 90 g/L;

10. Liver and kidney function: serum creatinine <= 1.5 times upper limit of normal; AST and ALT≤2.5 times upper limit of normal (ULN) or <= 5 times ULN in the presence of liver metastasis; Total bilirubin <=1.5 times upper limit of normal, or <= 2.5 times upper limit of normal if the patient has Gilbert's syndrome;

11. Subjects of childbearing age must agree to use effective contraception during the trial, and women of childbearing age must have a negative serum or urine pregnancy test;

12. Non-lactating patients;

Exclusion Criteria

1. Patients with prior abdominal or pelvic radiotherapy;

2. being mentally ill and unable to cooperate with treatment;

3. Serious uncontrolled medical diseases, such as serious internal medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.;

4. Unable to tolerate cisplatin chemotherapy;

5. receiving other experimental drugs or participating in clinical trials for other anticancer treatment purposes within 30 days before the first radiotherapy;

6. Severe infection within 4 weeks before study treatment, including but not limited to infectious complications requiring hospitalization, bacteremia, or severe pneumonia;

7. Human immunodeficiency virus (HIV) -positive persons;

8. HBsAg positive and HBV-DNA titer >= 1×10^3 IU/mL; Participants were eligible for inclusion if they were HBsAg positive and had a peripheral blood HBV-DNA level of < 1×10^3 IU/mL, and if the investigator considered the participant to be in a stable phase of chronic hepatitis B without increasing the risk to the participant.

9. Hepatitis C virus (HCV) antibody positive or human immunodeficiency virus (HIV) antibody positive and HCV RNA test positive;

10. Patients judged by the investigator to be ineligible for the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ping Jiang

Role: STUDY_DIRECTOR

Peking University Third Hospital

Locations

Peking University Third Hospital

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Junjie Wang professor

Role: CONTACT

junjiewang@pku.edu.cn

0086-17355240686

Facility Contacts

Zhichen Lin

Role: primary

1910301321@pku.edu.cn

86+13121135252

Other Identifiers

797-02

Identifier Type: -

Identifier Source: org_study_id